Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202821 | 0.89 | MAPT (0.43) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL5606168 | 0.85 | CYP2C19 (0.50) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL3271614 | 0.85 | HIF1A (0.52) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL29114282 | 0.83 | CYP1A2 (0.49) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| Methane SCHEMBL27483233 | 0.83 | HIF1A (0.50) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL10483819 | 0.82 | ALOX15 (0.47) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL4560574 | 0.82 | MAPT (0.52) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL11220671 | 0.81 | KIF11 (0.50) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL2030597 | 0.81 | MAPT (0.59) | MAPTKMT2ACYP1A2CYP3A4RECQL | |
| SCHEMBL1024478 | 0.81 | MAPT (0.59) | MAPTKMT2ACYP1A2CYP3A4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736330-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-1853581-B1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-06-02 | — | — | EP | disclosed |
| CN-101128453-A | 2-sulfinyl-and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors | MERCKLE GMBH (DE) | 2008-02-20 | — | — | CN | disclosed |
| EP-1853581-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006098554-A1 | NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006089798-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | MAPT 4464/4885KMT2A 2544/4885CYP1A2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.